Insulet Corporation (PODD)
NASDAQ: PODD · IEX Real-Time Price · USD
166.19
+2.02 (1.23%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Insulet Revenue
In the year 2023, Insulet had annual revenue of $1.70B with 30.02% growth. Revenue in the quarter ending December 31, 2023 was $509.80M with 37.90% year-over-year growth.
Revenue (ttm)
$1.70B
Revenue Growth
+30.02%
P/S Ratio
6.86
Revenue / Employee
$565,700
Employees
3,000
Market Cap
11.64B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
Dec 31, 2018 | 563.80M | 100.00M | 21.56% |
Dec 31, 2017 | 463.80M | 96.81M | 26.38% |
Dec 31, 2016 | 366.99M | 103.10M | 39.07% |
Dec 31, 2015 | 263.89M | 32.57M | 14.08% |
Dec 31, 2014 | 231.32M | -15.76M | -6.38% |
Dec 31, 2013 | 247.08M | 35.72M | 16.90% |
Dec 31, 2012 | 211.37M | 59.11M | 38.83% |
Dec 31, 2011 | 152.26M | 55.29M | 57.02% |
Dec 31, 2010 | 96.97M | 30.93M | 46.85% |
Dec 31, 2009 | 66.03M | 29.97M | 83.12% |
Dec 31, 2008 | 36.06M | 22.69M | 169.66% |
Dec 31, 2007 | 13.37M | 9.71M | 265.06% |
Dec 31, 2006 | 3.66M | 3.61M | 7,226.00% |
Dec 31, 2005 | 50.00K | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG & Co. KGaA | 21.62B |
DaVita | 12.14B |
Charles River Laboratories International | 4.13B |
Incyte | 3.70B |
Dr. Reddy's Laboratories | 2.99B |
Bruker | 2.96B |
United Therapeutics | 2.33B |
Medpace Holdings | 1.96B |
PODD News
- 24 days ago - Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 24 days ago - Nadav Eiron Joins Crusoe as Senior Vice President of Cloud Engineering - Business Wire
- 5 weeks ago - Insulet Appoints Ana Maria Chadwick as Chief Financial Officer - Business Wire
- 7 weeks ago - Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy - Business Wire
- 7 weeks ago - Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Business Wire
- 2 months ago - Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency) - Business Wire
- 2 months ago - Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference - Business Wire
- 2 months ago - Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor - Business Wire